It was interesting to hear that in April they had no idea why they were low in sales since January, and yet they still decided to affirm the Q1 guidance and went ahead with reporting preliminary results with very limited commentary, which cause more harm to share price than good. It puzzles me why would someone think it's a good thing to do?
In terms of their internal reporting, it begs a question how do they actually track their sales? should they be tracking it weekly? We're in May now and yet commentary provided is still vague.
And then this comment about organisational restructure - sounds like they found the guy to blame for?
Last one for me, on multiple occasions they've pointed out to slower conversion and VAC approvals - which is fine, things happen... but once they had learned about the speed of conversion and VAC approvals, why increase sales team again in April? Imagine if the FDA approval doesn't come through - the fallout from that will gigantic!
Overall, judging by where share price is and how thing have been handled in the past few months - Proposals 9 & 10 should receive a "NO" vote from shareholders. I doubt it won't pass but at least it will send a powerful signal 
